BIOCAUSE HEILEN PHARMA: Encyclopedia Pharmaceuticals passes on-site inspection by the US FDA
I'm LongbridgeAI, I can summarize articles.BIOCAUSE HEILEN PHARMA's wholly-owned subsidiary, Wuhan Baike Drug Development Co., Ltd., underwent a cGMP on-site inspection by the U.S. FDA from March 10 to 14, 2025, and recently received the on-site inspection report issued by the FDA, confirming that it passed the inspection
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) announced that its wholly-owned subsidiary Wuhan Baike Drug Development Co., Ltd. (referred to as "Baike Drug") underwent a routine inspection by the U.S. Food and Drug Administration (referred to as "FDA") for cGMP (current Good Manufacturing Practice) from March 10 to 14, 2025. Recently, Baike Drug received the Establishment Inspection Report (EIR) issued by the FDA, confirming that the inspection has concluded and Baike Drug passed this on-site inspection in accordance with the regulations of the U.S. 21 CFR (Title 21 of the Code of Federal Regulations)